SCHEMBL25801784

SCHEMBL25801784

CCOP(C)(=O)C(Cc1nc(Cc2ccc(-c3ccc(Cl)cc3)cc2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
TSHR P16473 4/20 0.38
SMPD1 P17405 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
ZAP70 P43403 2/20 0.36
SRC P12931 1/20 0.36
ERCC1 P07992 1/20 0.36
ERCC4 Q92889 1/20 0.36
HTT P42858 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
MAPK1 P28482 2/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25801748 0.97 MAPT (0.41) MAPTTSHRSMPD1KDM4EALDH1A1
SCHEMBL25804685 0.92 MAPT (0.40) MAPTTSHRSMPD1KDM4EALDH1A1
SCHEMBL25801750 0.89 TRPA1 (0.37) MAPTHTTSMN1; SMN2CYP1A2CYP2D6
SCHEMBL23588157 0.89 MAPT (0.41) MAPTTSHRSMPD1KDM4EALDH1A1
SCHEMBL25804329 0.89 MAPT (0.41) MAPTTSHRSMPD1KDM4EALDH1A1
SCHEMBL25801969 0.88 MEN1 (0.35) MAPTTSHRZAP70SRCMEN1
SCHEMBL25801777 0.88 MEN1 (0.35) MAPTTSHRZAP70SRCMEN1
SCHEMBL25801774 0.88 KMT2A (0.36) MAPTTSHRALDH1A1HPGDZAP70
SCHEMBL25801972 0.88 MEN1 (0.35) MAPTKDM4EHPGDZAP70SRC
SCHEMBL25801773 0.88 TSHR (0.44) TSHRZAP70SRCHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 MAPT 4683/4885TSHR 3550/4885SMPD1 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.